AcelRx Reaches Licensing Deal For DZUVEO In Europe And In-licensing Deal For Two Products In US

(RTTNews) - AcelRx Pharmaceuticals Inc. (ACRX) said that it has reached agreements with Laboratoire Aguettant providing Aguettant with a license to commercialize DZUVEO in Europe, and providing AcelRx with two pre-filled syringe product candidates for the U.S.

As per the DZUVEO licensing deal, Aguettant will have the right to commercialize DZUVEO in Europe.

AcelRx is entitled to receive up to about $55 million in a combination of up-front and sales-based milestone payments at various annual sales levels from Aguettant, along with revenue share payments ranging from 35% to 45% of net sales.

AcelRx will manufacture and supply DZUVEO to Aguettant at an agreed supply price.

In a separate licensing agreement, AcelRx obtained the rights to file NDAs, commercialize in the United States two of Aguettant's EU-approved, pre-filled syringe products - ready-to-use ephedrine and phenylephrine. Aguettant has the right to receive up to $24 million in sales-based milestone payments, at various annual sales levels up to $60 million, along with revenue share payments of 40 to 45% of the net sales of the two pre-filled syringe products, if approved in the U.S. by the Food and Drug Administration.